Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Sponsored Content | Blog | Greg Freiherr, Industry Consultant | PET Imaging | November 07, 2018

What Precision Means To PET

PET images taken on Philips’ Vereos PET/CT at Methodist Hospital in Omaha, Neb., show a lung lesion. Caveat: Because results may vary, “results from case studies are not predictive of results in other cases,” Philips cautioned. Images courtesy of Omaha’s Methodist Hospital

Precision can have an enormous impact on patients.

From diagnosis to patient monitoring (see How Digital PET/CT Can Improve Clinical Care), from the selection of therapy to its assessment (see “Digital PET Balances Scan Time and Resolution”), the digital detector built into Philips Vereos PET/CT makes positron imaging precise. (See Why - And How - Digital PET Is Better Than Analog.”)

The digital detector, and the Vereos digital architecture, are a big part of the scanner’s efficiency, said Tom Brennan, service leader of Imaging for Nebraska Methodist Health Systems in Omaha, Neb. Staff at its Methodist Hospital in midtown Omaha use Vereos PET/CT to do seven PET scans a day — and about 20 CTs. Slots for PET patients are scheduled in pairs. In between, Vereos’ 64-slice CT handles patients who can’t be seen on the three CT scanners on the main campus or a fourth at a neighboring hospital in the network.

The need to do double duty on the hybrid scanner is why speed was a big factor in the choice of Vereos, said Brennan: “Because we share the system with CT, we have a lot of patients who want to get in, so we have to use (Vereos) efficiently.”

Because Vereos includes a 64-slice Ingenuity CT from Philips, “anything you can do with an Ingenuity CT you can do with the Vereos CT,” said Karim Boussebaa, Philips’ business leader for CT/Advanced Molecular Imaging.

 

Efficiency

Vereos was chosen by Methodist Hospital to replace an aging analog system, one that also handled overflow CT scans “but didn’t do nearly as well,” Brennan said. The analog system “was much slower and less reliable.”

Brennan credits the digital architecture of Vereos for making “it a more reliable system.”

Equipped as it is with time-of-flight and digital imaging, Vereos provides a leap forward in clinical performance, he said. Improved diagnostic performance is buoyed by the hybrid scanner’s efficiency as the scanner is routinely applied to serve two types of patients — those who need just CT and others who need positron imaging.

The vast majority of PET scans are oncologic, according to Brennan, who explains that the main campus hosts a major cancer center. Fluorine-18 deoxyglucose (FDG) is the radiotracer of choice, although gallium 68 is occasionally applied to visualize neuroendocrine tumors and yttrium-90 is used to treat and visualize liver metastases. The staff sometimes — but rarely — performs a myocardial viability study, Brennan noted.

Vereos’ digital technology can be leveraged to reduce radiopharmaceutical dosing. At Methodist Hospital in Omaha, staff inject lower doses of PET radiopharmaceuticals than when they used Vereos’ analog predecessor. Doses of FDG now are typically 30 percent lower than ones administered to patients before the hospital switched from an analog PET/CT to Vereos in early summer, according to Brennan. This has allowed the hospital to take advantage of the lower pricing tier of FDG that is available to Methodist Hospital.

“We went from a weight-based dosing system to one of standardized doses of just 12 mCi,” Brennan said. “What that did for us it dropped all of our doses into that lower price tier, which saves us about $25,000 per year.”

High efficiency is possible with no compromise in image quality because of the one-to-one coupling between sensor and scintillation event. “Each of the 23,000 detectors has its own little counting chip, which I think leads to the amazing spatial resolution,” Brennan said. “That goes back to the heart of why it is fast and why the image quality is so good.”

Efficiency may be further boosted on the CT side through workflow improvements achieved using Philips’ iPatient software. In a study involving multiphasic liver CT exams, iPatient reduced time-to-results by 24 percent and clicks per exam by 66 percent. [The study was performed by Nicholas Ardley (Southern Health) and Kevin Buchan and Ekta Dharaiya (Philips Healthcare).]

At Omaha’s Methodist Hospital PET, scan times have dropped from 24 to 12 minutes on the Vereos compared to the preceding analog system, according to Brennan. Patient slots have been reduced from 45 to 30 minutes. This has resulted in greater availability of PET and CT exams.

“Even though we use the same prep time, we have added seven (CT) patient slots,” he said.

The increased efficiency achieved with Vereos means Methodist Hospital patients not only spend less time being scanned but less time waiting for appointments. This is important because “three out of our four patients are return patients. Vereos is the preferred tool to measure how treatments are going,” Brennan said.

Staying on schedule is very important for these patients, he said, because they typically depend on having results from multiple tests available at the same time: “So access is important. The speed of Vereos has helped us become better at getting patients in on time.”

 

Extending Patient Comfort

Patient comfort depends on feeling good. And Philips’ Ambient Experience directly addresses this in several modalities including CT and PET. “Ambient has shown some good results for reducing the level of stress,” said Philips executive Boussebaa. “It can really make a difference with kids.”

A mix of lighting and sound — movies projected on walls, for example — might combine to reduce stress, he said. These combinations can increase patient satisfaction, which has become a major survey item for hospitals.

Greater patient comfort can make patients easier to manage, which can make technologists’ jobs easier. In this way, Philips’ Ambient Experience improves working conditions for staff.

“The question is how to make people happy,” he said. “If you do that, patients will come back and staff will stay.”

According to Boussebaa, health care administrators are coming to realize that patient comfort has a role in being efficient and effective.

With its emphasis on precision, Vereos addresses patient comfort, the components of value-based medicine — and the future.

 

Editor's note: This is the fourth blog in a series of five on digital PET/CT. The first blog, “How Digital PET/CT Can Improve Clinical Care,” can be found here. The second blog, “Why - And How - Digital PET Is Better Than Analog,” can be found here. The third blog, “Digital PET Balances Scan Time and Resolution,” can be found here.

 

Related Content:

SPECIAL SUPPLEMENT: Examining the Value of Digital PET/CT

Related Content

A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

Figure 1. Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included participants with clinical mild cognitive impairment and dementia. Higher rates of tau accumulation were observed in participants on the AD continuum (CU Aβ+ve and CI Aβ+ve). Participants with the highest baseline tau and rates of tau accumulation were younger and more likely to be CI Aβ+ve. Image courtesy of SNMMI

News | PET Imaging | June 16, 2021
June 16, 2021 — A novel positron emission tomography (PET
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame

Figure 1. A: COVID-19-related spatial covariance pattern of cerebral glucose metabolism overlaid onto an MRI template. Voxels with negative region weights are color-coded in cool colors, and regions with positive region weights in hot colors. B: Association between the expression of COVID-19-related covariance pattern and the Montreal Cognitive Assessment (MoCA) score adjusted for years of education. Each dot represents individual patient. C: Results of a statistical parametric mapping analysis. Upper row illustrates regions that show significant increases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the subacute stage (paired t test, p < 0.01, false discovery rate-corrected). Bottom row depicts regions that still show significant decreases of normalized FDG uptake in COVID-19 patients at 6-months follow-up compared to the age-matched control cohort at an exploratory statistical threshold (two-sample t test, p < 0.005). Image Credit: G Blazhenets et al., Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg

News | PET Imaging | June 16, 2021
June 16, 2021 — The effects of COVID-19 on the b
A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.

Result of the Hoffman brain phantom study. Top row: same PET slice reconstructed with A) 2mm static OSEM, B) 1mm static OSEM, C) proposed SR method and D) corresponding CT slice (note that the CT image can be treated as a high-resolution reference). Middle row: zoom on region of interest for corresponding images. Bottom row: Line profiles for corresponding data. Image created by Y Chemli, et al., Gordon Center for Medical Imaging: Department of Radiology Massachusetts General Hospital, Harvard Medical School, Boston, MA.

News | PET Imaging | June 14, 2021
June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as...
News | PET-CT | June 10, 2021
June 10, 2021 — Bringing the power of...
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

Getty Images

News | PET Imaging | June 07, 2021
June 7, 2021 — The U.S.
According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary lymph node or ipsilateral deltoid uptake is occasionally observed on FDG or 11C-choline PET performed after Pfizer-BioNTech or Moderna COVID-19 vaccination

(A) 57-year-old woman with right upper arm melanoma who received the first dose of the COVID-19 vaccine (Pfizer-BioNTech) in the left deltoid 15 days prior to FDG PET/CT. FDG uptake is observed within left axillary lymph nodes (arrow, SUVmax = 9.3).

(B) 62-year-old man with metastatic prostate carcinoma who received the second dose of COVID-19 vaccine (Pfizer-BioNTech) in the right deltoid 7 days prior to 11C-choline PET/CT. 11C-choline uptake is observed within right axillary lymph nodes (arrows, SUVmax = 3.1) as well as the right deltoid muscle (circle, SUVmax = 1.7).

News | Coronavirus (COVID-19) | May 19, 2021
Overall Excellence Finalist/Multi-platform Package of the Year for its coverage of the Pandemic’s Toll on Radiology, National

Overall Excellence Finalist/Multi-platform Package of the Year for its coverage of the Pandemic’s Toll on Radiology, National

Feature | Imaging Technology News - ITN | May 17, 2021 | By Melinda Taschetta-Millane